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Abstract: Hollow fiber artificial lungs are increasingly being
used for long-term applications. However, clot formation limits
their use to 1–2 weeks. This study investigated the effect of ni-
tric oxide generating (NOgen) hollow fibers on artificial lung
thrombogenicity. Silicone hollow fibers were fabricated to
incorporate 50 nm copper particles as a catalyst for NO genera-
tion from the blood. Fibers with and without (control) these
particles were incorporated into artificial lungs with a 0.1 m2
surface area and inserted in circuits coated tip-to-tip with the
NOgen material. Circuits (N ¼ 5/each) were attached to rabbits
in a pumpless, arterio-venous configuration and run for 4 h at
an activated clotting time of 350–400 s. Three control circuits
clotted completely, while none of the NOgen circuits failed.
Accordingly, blood flows were significantly higher in the
NOgen group (95.9 6 11.7, p < 0.01) compared to the controls
(35.2 6 19.7; mL/min), and resistance was significantly higher
in the control group after 4 h (15.38 6 9.65, p < 0.001) than in
NOgen (0.09 6 0.03; mmHg/mL/min). On the other hand, plate-
let counts and plasma fibrinogen concentration expressed as
percent of baseline in control group (63.7 6 5.7%, 77.2 6 5.6%;
p < 0.05) were greater than those in the NOgen group (60.4 6
5.1%, 63.2 6 3.7%). Plasma copper levels in the NOgen group
were 2.8 times baseline at 4 h (132.8 6 4.5 lg/dL) and
unchanged in the controls. This study demonstrates that NO
generating gas exchange fibers could be a potentially effective
way to control coagulation inside artificial lungs. VC 2013 Wiley
Periodicals, Inc. J Biomed Mater Res Part A: 101A: 3511–3519, 2013.
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INTRODUCTION
Hollow ﬁber artiﬁcial lungs are increasingly being used for
long-term applications. These applications include extracor-
poreal membrane oxygenation, pumpless arterio-venous car-
bon dioxide removal, and thoracic artiﬁcial lungs. However,
thrombosis often limits the longevity of extracorporeal
membranes. Blood contact leads to clot formation, increased
resistance, and decreased gas exchange efﬁciency.1–4 Fur-
thermore, shed thromboemboli from these devices can
cause organ dysfunction. Antithrombotic coatings for blood-
contacting surfaces including membrane lungs are avail-
able,5–10 but these coatings have not worked well enough to
markedly reduce clot formation or eliminate the need for
systemic anticoagulation.
One possible solution to this problem is the use of NO
ﬂux from the surfaces of the artiﬁcial lung. Nitric oxide
(NO) is a short-acting, potent platelet inhibitor that is
normally produced by endothelial cells.11 The half-life of NO
is only 2–5 s in blood.12 As a result, NO delivery from poly-
mer surfaces has been examined as a means to focus antico-
agulation solely at the biomaterial surface without systemic
effects or cell damage.13 Accordingly, previous studies have
shown that platelet adhesion is reduced on polymers that
either release stored NO or generate it from NO donors in
blood if the NO ﬂux exceeds that of the endothelium.14,15
The goal of this study was to examine the effect of NO
generating (NOgen) surfaces in artiﬁcial lungs for the ﬁrst
time. Silicone (polydimethylsiloxane) gas exchange ﬁbers
were thus manufactured to incorporate Cu particles. The Cu
particles catalyze NO formation in blood via decomposition
of circulating s-nitrosothiols via the mechanism in Figure
1A.16–18 NO generation and clotting have both been shown
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to be linearly related to surface expression of Cu.19 These
ﬁbers were incorporated in miniature artiﬁcial lungs, which
were inserted into a circuit that was similarly coated tip-to-
tip with the NOgen material. The circuit was then evaluated
for thrombogenicity for a period of 4 h in a pumpless arte-
rio-venous circulation model in rabbits.
MATERIALS AND METHODS
Circuit components
Radial ﬂow artiﬁcial lungs were constructed with NOgen or
pure silicone hollow ﬁbers [Fig. 2(A)]. Both ﬁber types were
constructed at Medarray, Inc (Ann Arbor, MI) using a propri-
etary two-part silicone formulation (MedArray Inc, Ann
Arbor MI). NOgen ﬁbers were doped with 10 wt% of 50 nm
Cu particles (Sigma Aldrich, St. Louis, MO). The hollow
ﬁbers had an average inner and outer diameter of 100 and
160 lm. Each ﬁber bundle had a path length, axial length,
and void fraction of 1.1 6 0.2 cm, 2.7 6 0.5 cm, and 0.37
respectively. The prime volume and surface area were 20
mL and 0.09 m2. To examine the non-thrombogenicity of NO
generating artiﬁcial lungs in short-term experiments, a
dense, aggressive artiﬁcial lung design is required to accel-
erate clot formation. The ﬁber bundle’s void fraction was
thus 33% compared to a typical value of 50% in a commer-
cial oxygenator. Void fraction is deﬁned as 1-(solid space/
total space), where solid space is the volume occupied by
ﬁber material and total space is the sum of void volume
and ﬁber material volume. The linear ﬁber density was thus
50 ﬁbers/cm, resulting in only a 200 lm space per ﬁber.
Panel B in Figure 1 shows a 40 lm linear ﬁber spacing of
our artiﬁcial lungs compared to a 70 lm linear ﬁber spacing
of commercial lungs [Fig. 1(C)]. This design speeds up de-
vice failure due to coagulation.
The test circuit was a pumpless arterio-venous (AV)
shunt (Fig. 3). The inlet to outlet circuit components were
each a 16 (inlet) or 14 (outlet) gauge angiocath, 1/400 luer
lock PVC connector, 300 long 1/400 inner diameter (ID) tygon
(Fisher Scientiﬁc, Pittsburg, PA) tubing, a 1/400–1/400 luer
lock straight polycarbonate connector, and another 300 long
1/400 ID tygon tubing section. The NOgen shunts were
coated tip-to-tip with either the two-part silicone or with 10
wt% of 50 nm Cu(II) oxide particles (Sigma Aldrich, St.
Louis, MO, Product number 544868) in tygon polymer. NO-
gen silicone was used to coat the angiocaths and connectors
FIGURE 1. (A) A model of Cu-mediated NO generation from circulating S-nitrosothiols by hollow fiber membrane lungs for platelet inhibition,
(B) the linear fiber spacing of NOgen lungs, and (C) that of commercial lungs.
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in either silicone using the synthesis procedure described
previously.19 To coat tubing, tygon pellets chopped up from
tygon tubing were dissolved in tetrahydrofuran (THF; Sigma
Aldrich, St. Louis, MO) using 1 g pellets per 3 mL THF by
vortexing the mixture for 30 min. Cu particles were then
suspended in the solution and mixed. Speciﬁcally, the Cu sil-
icone mixture was thoroughly mixed at 2600 rpm for 30
min using a 120 V model Analog Vortex Mixer (Fisher Scien-
tiﬁc) followed by mixing at 3500 rpm for 1 min using a
DAC 150.1 FV SpeedMixer (FlackTek, SC). The resulting mix-
ture was then coated onto the circuit tubing and cured at
room temperature for 48 h.
Measurement of NO ﬂux from ﬁbers in vitro
NO generation was measured from 1 cm long tubing sam-
ples (NOgen and non-NOgen surfaces, N ¼ 5 ea), and from
1 cm long ﬁbers (NOgen and non-NOgen, N ¼ 5 ea) using a
Seivers nitric oxide analyzer (NOA), model 280 (Boulder,
CO) according to previously described methods.19. In brief,
S-nitrosoglutathione (GSNO, 1 lM), 30 mM glutathione, and
5 mM ethylenediaminetetraacetic acid, all purchased from
Sigma Aldrich, were added to an amber reaction vessel con-
taining phosphate-buffered saline (PBS, pH ¼ 7.34) at 37C.
The solution was purged with nitrogen gas and the output
gas was swept to a nitric oxide analyzer (GE Analytical
Instruments, Boulder, CO) at 200 mL/min. Baseline meas-
urements were taken for 5 min before samples were intro-
duced into the GSNO-rich solution. The NO generated from
the reaction was continuously measured, and a peak NO
ﬂux was calculated by dividing the peak NO generation rate
by the sample surface area.
Rabbit thrombogenicity model for testing
extracorporeal circulation (ECC) circuits
The animal handling and surgical procedures were
approved by the University Committee on the Use and Care
of Animals in accordance with University of Michigan and
federal regulations. A total of 10 ECC circuits (N ¼ 5/group)
were tested for thrombogenicity using 10 adult New Zea-
land male rabbits (Myrtle’s Rabbitry, Thompson’s Station,
TN). All rabbits (2.5–3.5 kg) were initially anesthetized with
intramuscular injections of 5 mg/kg xylazine injectable
(AnaSed Lloyd Laboratories Shenandoah, Iowa) and 30 mg/
kg ketamine hydrochloride (Hospira, Lake Forest, IL). Proce-
dures for maintenance rabbits under anesthesia, maintaining
normal blood pressure, surgical procedure for placement of
the AV circuit, measuring blood gases (arterial blood pH,
FIGURE 2. (A) Design of radial flow ECMO oxygenator (Borrowed with permission from Medarray). (B) Prototype of nitric oxide generating hol-
low silicone fiber oxygenator and (C) SEM (15 kV) image of NOgen silicone fiber surface showing copper catalysts. Prior to imaging, fibers were
gold sputtered.
FIGURE 3. Extracorporeal circulation circuits: (A) Control (clear) and
(B) NO-generating (bottom).
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pCO2, pO2, total hemoglobin and methemoglobin), and
measuring coagulation have all been previously pub-
lished.14,15,20 No sweep gas was employed in the ﬁbers, as
subjects were adequately supported on a Sechrist Infant
Ventilator Model IV-100 (Sechrist, Anaheim, CA).
The circuit was primed with saline solution and 6 U/mL
of heparin sulfate and placed into position by cannulating
the left carotid artery for circuit inﬂow and the right external
jugular vein for circuit outﬂow. The rabbits were given a hep-
arin bolus (300 U/kg, IV). Activated clotting time (ACT) was
measured with a hemochron blood coagulation system model
801 (International Technidyne, Edison, NJ) using 0.4 mL of
blood. Once ACT was within 350–400 s, the circuit was
unclamped and a 10 U/kg/h heparin infusion was initiated.
In addition, 0.12 lmol/kg/min infusion of the NO donor, S-
Nitroso-N-acetylpenicillamine (SNAP), was started immedi-
ately after the ECC blood ﬂow was initiated to replace any
lost NO donors in blood. Blood ﬂow was monitored with an
ultrasonic ﬂow probe and ﬂow meter (1/400 ME6PXN and
HT207, respectively; Transonic, Ithaca, NY). Circuit inlet and
outlet pressures were measured using ﬂuid coupled pressure
transducers (Hospira, Lake Forest, IL) and a data acquisition
system (Biopac Systems, Aero Camino Goleta, CA). Pressures
and ﬂow were recorded at the onset of blood ﬂow and every
30 min thereafter. In addition, blood samples were collected
every hour for measurement of blood gases, platelet and
total white blood cell (WBC) counts, plasma ﬁbrinogen con-
centration, activated clotting time (ACT), and platelet aggre-
gation as performed at baseline. After 4 h, the rabbits were
euthanized with Fatal Plus (130 mg/kg sodium pentobarbital;
Vortech Pharmaceuticals Dearborn, MI). The circuits were
then ﬁxed in 2% glutaraldehyde and autopsied for clot
inspection on their gas exchange ﬁbers using scanning elec-
tron microscopy. To perform autopsy on the artiﬁcial lungs,
their ﬁber bundles were excised by sectioning away the
potted regions of the devices. The ﬁber bundles were dehy-
drated by bathing them with a graded series of ethanol–
water mixtures from 25, 50 and 75 to 100% ethanol for 10
min each, and then dried for 30 min. Dried ﬁbers were sput-
ter-coated with gold, and imaged with a Hitachi S-3200N
scanning electron microscope (15 kV).
Data and statistical analysis
All raw hematology data collected after baseline was cor-
rected for hemodilution by multiplying the raw data col-
lected at time t with (hemoglobin at BL/hemoglobin at time
t). For example, platelet count corrected for hemodilution at
t ¼ 1 h will be calculated as Platelet countt ¼ 1 h corrected ¼
(hemoglobint ¼ baseline/hemoglobint ¼ 1 h)  platelet
countt ¼ 1 h. Resistance was calculated in the standard fash-
ion as the average pressure drop across the circuit divided
by the average ﬂow rate.
All statistics were performed using SPSS (Chicago, IL).
Data normality was assessed using a Shapiro–Wilk test for
each dependent variable (mean arterial pressure, circuit
ﬂow, artiﬁcial lung resistance, platelet count, plasma ﬁbrino-
gen, and resistance). P-values from the tests of normality
were all greater than 0.05, indicating that the data was nor-
mally distributed. Mixed model analysis with repeated
measures was then used to determine the effect of circuit
type (NOgen or control) on each dependent variable. Experi-
mental time was used as the independent, repeated vari-
able, and the experiment number was the subject variable.
In each case, the baseline data points were excluded as this
data is taken prior to application of the treatment (NOgen
or control). Finally, alternative covariance structures were
compared using information criteria (e.g., AIC, BIC). In all
cases, a Toeplitz covariance structure was found to have the
best ﬁt. In addition, a similar mixed model was performed
to determine if each independent variable varied signiﬁ-
cantly from baseline, using the following exceptions: (1) the
NOgen and control data was analyzed separately, (2) the
baseline data was included, and (3) a Bonferroni correction
was used when comparing each time to baseline. A p-value
TABLE I. Effects of NO Generating Surface on Hemodynamic Parameters of the Extracorporeal Circulation (ECC) Circuits and
Rabbits
Time on ECC (h)
Treatment Parameter Baselinea 1 2 3 4
Control ECC MAP 39.0 6 6.0 41.80 6 18.80 59.50 6 23.30 89.0 6 45.30* 93.50 6 43.10*
HR 201.80 6 30.30 208.80 6 22.5 253.50 6 14.80* 248.50 6 13.40 204.0 6 14.10
ECC BF 63.20 6 2.10 22.80 6 14.0* 26.20 6 19.40* 30.0 6 24.40* 33.80 6 32.80*
ACT 331.0 6 36.70 337.0 6 58.0 314.5 6 19.3 276.50 6 18.0 307.506 38.90
PaCO2 30.33 6 5.80 29.60 6 4.0 31.0 6 0.90 30.8 06 1.10 28.70 6 2.54
pH 7.48 6 0.01 7.44 6 0.10 7.3.0 6 0.10 7.33 6 0.11 7.32 6 0.01
NOgen ECC MAP 48.60 6 6.20 34.40 6 2.60* 46.80 6 28.60 54.0 6 16.20 52.20 6 22.70
HR 185.80 6 30.40 193.60 6 12.80 195.20 6 17.60 194.40 6 10.90 202.60 6 5.10
ECC BF 70.50 6 6.90 83.20 6 6.50 105.20 6 20.40* 112.60 6 14.40* 105.0 6 8.70*
ACT 362.0 6 43.40 401.80 6 45.60 393.20 6 26.90 371.20 6 20.90 376.80 6 19.40
PaCO2 35.92 6 5.70 35.10 6 9.89 33.70 6 10.07 34.76 6 7.98 35.66 6 6.84
pH 7.43 6 0.02 7.32 6 0.11 7.31 6 0.11 7.28 6 0.09 7.31 6 0.05
Values are means 6 SEM.
* p < 0.05 versus baseline; Mixed model analysis with repeated measures.
a Values are just after establishing flow in ECCs. MAP ¼ mean arterial pressure (mm Hg), HR ¼ heart rate (beats/min), BF ¼ blood flow (ml/
min), ACT ¼ activated clotting time (sec), PaCO2 ¼ arterial partial pressure of CO2.
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< 0.05 is regarded as signiﬁcant. Kaplan–Meier analysis was
used to estimate the survival of circuit type, and statistical
differences in all baseline data between circuit types were
analyzed using a student t-test.
RESULTS
In vitro NO ﬂux from ﬁbers
The NO ﬂux from ﬁbers and tubing containing 10 wt% Cu
particle (50 nm) were 12 6 4  1010 mol/cm2/min and
14.7 6 2.5  1010 mol/cm2/min, respectively. Addition of
the control ﬁbers and circuits to the NO donor media
resulted in no additional NO release over baseline readings.
General rabbit physiology
Table I presents general rabbit physiology in each group.
Baseline data on PaO2, pH, and mean arterial pressure
(MAP) were signiﬁcantly different between circuit types at p
¼ (0.01, 0.008, 0.04), respectively. Baseline data were taken
minutes after initiating blood ﬂow. In Table I, baseline MAP
in both NOgen and control groups were lower than normal
rabbit MAP. In addition, baseline data on blood ﬂow, PaCO2,
and heart rate were not different between circuit group at
p ¼ (0.28, 0.58, and 0.42), respectively. Over the course of
the study, heart rate and MAP were signiﬁcantly higher in
the control group (223.0 6 25.6 bpm, 64.5 6 25.0 mmHg)
than in the NOgen group (194.7 6 6.1 bpm, 42.7 6 7.7
mmHg; p < 0.05) due to the vasodilatory effect of NO on
blood vessels. Partial pressures of CO2, O2, and pH were
relatively normal and stable in the control (30.1 6 2.9
mmHg, 125.8 6 3.1 mmHg, 7.39 6 0.05) and NOgen (35.0
6 8.10 mmHg, 289.8 6 15.2 mmHg, 7.33 6 0.08) groups.
There was minor acidosis in the NOgen group, which may
be due to greater AV shunt ﬂow and resultant reduced
peripheral perfusion (see below).
ECC blood ﬂow and artiﬁcial lung resistance
The Kaplan–Meier survival for ﬂow in control and NOgen
circuits is shown in Figure 4. All NOgen circuits remained
patent for the entire test duration. In contrast, two control
circuits had no blood ﬂow after 30 min and one more had
none after 60 min. For the remaining controls, one main-
tained at least baseline ﬂows while the other had ﬂows
signiﬁcantly less than baseline levels (p < 0.01). On the
other hand, blood ﬂow increased from baseline levels
almost approaching signiﬁcance (p ¼ 0.07; Fig. 5) in the
NOgen group. This may be due to a combination of no sig-
niﬁcant change in resistance (see below) and the increase
in mean arterial pressure that occurs over the course of the
experiment. Blood ﬂow through these circuits is driven by
the pressure gradient between the artery and vein. Initiation
of blood ﬂow led to arterial hypotension volume shifts and
likely an inﬂammatory response to the artiﬁcial circuits. The
hypotension then lessened over the course of the experi-
ment. This may have been due to a compensatory increase
in cardiac output, but this data was not taken. Ultimately, as
the arterial pressure increased, ECC ﬂow also increased in
the relatively clot-free NOgen groups, but the increment was
small and not signiﬁcantly different from baseline ﬂow.
The decrease in ﬂow in the control group was due to an
increase in resistance due to thrombus formation. The re-
sistance in the NOgen circuits (dark bars) and control
FIGURE 4. Survival of control and experimental ECC circuits after
flow initiation. FIGURE 5. Time course blood flow in control and NOgen ECC
circuits.
FIGURE 6. Time course blood flow resistance in control and NOgen
ECC circuits.
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circuits (clear bars) is shown in Figure 6. Resistance did not
change signiﬁcantly with time in the NOgen group (p <
0.01). In the control group, all resistances from 30 to 240
min were signiﬁcantly higher than baseline resistance (p <
0.01). Resistance in the control group raised from 0.08 6
0.06 mmHg min/mL at baseline to 21 6 9 mmHg min/mL
at 30 min. Thereafter, devices with inﬁnite resistance (zero
blood ﬂow) were removed from the data as they failed, but
resistance values remained over 5.5 6 2.5 mmHg min/mL
for the two devices that retained some blood ﬂow. Autopsy
results from control and NOgen lungs, shown in Figures 7
(gross, ﬁber level view) and 8 (ﬁne, surface topography),
revealed signiﬁcantly less clot formation on the NOgen
lungs’ gas exchange ﬁbers compared to controls. It can be
seen quite starkly that clot formation on the control lungs
led to their increased resistance to blood ﬂow, decreased
ﬂow, and failure. Moreover, as expected, it can be seen that
clot formation is more severe in control devices that failed
than in those that did not fail.
Hematology
Activated clotting times were generally higher in NOgen
than in control group. At baseline, ACT in NOgen (362.0 6
97.2 s) was not signiﬁcantly higher than control (385.8 6
82.3, p ¼ 0.68). It also did not increase or decrease
signiﬁcantly after 4 h of blood ﬂow in NOgen (376.5 6
86.9, p ¼ 0.76) and control (307.5 6 86.9, p ¼ 0.3) groups,
respectively. Methemoglobin levels remained below 0.9 6
0.3% of total hemoglobin in all circuits. In both control and
NOgen groups, platelet counts dropped signiﬁcantly (p <
0.05) to 58.3 6 5.6% and 53.5 6 4.3% of baseline counts,
respectively, after an hour of extracorporeal circulation
(ECC; Fig. 9). In addition, the duration of blood ﬂow had an
effect on platelet count (p < 0.01) but not plasma ﬁbrino-
gen (p ¼ 0.21). Between hour 1 and 4, platelet counts and
plasma ﬁbrinogen did not change in control group now of
size N ¼ 2, whereas only platelet count was signiﬁcantly
lower at hour 4 in NOgen group (p < 0.05) compared to
hour 1 (Fig. 9). White blood cell counts (Fig. 10) were sig-
niﬁcantly higher in the controls circuits (p < 0.05). White
blood counts signiﬁcantly increased from baseline (p <
0.05), peaking at 200% of baseline after 2 h of blood ﬂow
in controls. In the NOgen group, a slight and insigniﬁcant (p
¼ 0.14) rise in WBC was observed at 1 h and thereafter
returned to baseline values.
Plasma copper concentration
Serum copper level at the onset of blood ﬂow in control
group (132.8 6 4.5 lg/dL) was not signiﬁcantly different
from the NOgen group (134.7 6 22.5 lg/dL, p < 0.01). As
expected, baseline copper level was maintained for 4 h in
the control group (p < 0.01). However, plasma copper levels
FIGURE 7. Scanning electron micrographs of the artificial lung fibers showing clot formation on the outer layers of fibers from (A) a failed con-
trol lung, (B) a control lung that survived 4 h, and (C) a NOgen lung.
FIGURE 8. Scanning electron micrographs of the artificial lung fiber surfaces of (A) control and (B) NOgen fibers taken from fiber layers in the
middle of the device. Control surfaces contain far more platelet deposition than NOgen surfaces.
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in the NOgen group signiﬁcantly increased to 2.8 times
baseline levels (p < 0.001).
DISCUSSION
The aim of this study was to develop a copper-mediated,
NO generating, hollow ﬁber membrane lung, and evaluate
its thrombogenicity. These ﬁbers were created successfully
and capable of 12 6 4  1010 mol/cm2/min of NO ﬂux. It
should be noted that NO ﬂux is calculated in the traditional
way as moles of NO release per unit time per unit area.
Therefore, as the same amount of Cu (10 wt% of Cu/poly-
mer matrix) was added to ﬁbers and to tubing, both surfa-
ces had similar catalytic activity on NO donors and thus
similar rate of NO release per unit area. Previous 10 wt%
surfaces with either 3 lm19 and 50 nm21 copper particles
produced 9  1010 and 15  1010 mol/cm2/min, respec-
tively, under identical in vitro conditions. Due to the NO
ﬂux, the NOgen ECC lungs were less thrombogenic than
their non-NOgen controls. The NO generating ECC lungs
showed markedly less surface clot formation and were thus
all patent for the duration of the study. In contrast, 60% of
the control lungs clotted off enough to completely eliminate
blood ﬂow after an hour of circulation.
It should be noted that the artiﬁcial lung ﬁber bundle
design presents an exceedingly challenging test for evaluat-
ing biocompatibility. As discussed earlier, the ﬁber bundles
were packed very densely to maximize artiﬁcial surface and
hasten coagulation. There is only an average of 40 lm
between adjacent ﬁbers and, moreover, adjacent ﬁber layers
are directly touching with no space between them. Thus,
even a small amount of thrombus can markedly occlude the
blood ﬂow path. In the NO lungs, platelet binding appears
to be largely eliminated, keeping these narrow channels
open.
Despite these positive results, systemic platelet counts
did not differ between the NOgen and control groups. For
this to be true, all experiments must have resulted in the
same loss of platelets. Yet, SEMs indicate very little platelet
binding to the NOgen lungs and signiﬁcant binding on the
control lungs. Several issues might explain this paradox.
First, only two control devices remained patent at 1 h.
Thus, the low survival rate in the control group means that
platelet consumption data for the control group shown in
Figure 9 is largely representative of the two surviving con-
trol devices. These devices had a lesser amount of clot for-
mation and platelet binding. Second, it is our hypothesis
that NO reduced platelet binding to the lungs but did not
fully eliminate platelet activation in ﬂowing blood due to
surface-generated, pro-coagulant molecules such as throm-
bin. In this scenario, platelets would continue to pass
through the lung but would then be removed in the rabbit
by the mononuclear phagocyte system.22,23. The hypothesis
of surface-generated thrombin, which induces activation of
circulating platelets, is supported by the fact that plasma
proteins of the contact system of the coagulation cascade
can still adsorb to prosthetic surfaces even in the presence
of NO.16,24 Adsorption of contact system proteins such as
FXII and kallikrein lead to thrombin generation in plasma,
which in turn activates ﬂowing platelets.16,25
To that point, ﬁbrinogen adsorption was larger in the
NO-generating group than in controls. Greater ﬁbrinogen
adsorption has been observed in previous blood studies
where copper particles were coated onto circuit tubing.15
This effect could be due to a rougher NOgen surface or due
to charge interaction between the polymer surface, where
an oxidation–reduction reaction is constantly taking place,
and the polar terminals of plasma ﬁbrinogen. The mecha-
nisms of interaction among the NOgen surface, NO
FIGURE 10. Time course white blood cell counts in control and
NOgen ECC circuit groups.
FIGURE 9. Levels of platelet consumption and plasma fibrinogen con-
centration during extracorporeal circulation.
ORIGINAL ARTICLE
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A | DEC 2013 VOL 101A, ISSUE 12 3517
generation and ﬁbrinogen activation is, however, still not
clear.14,26,27 Future studies, therefore, should examine pro-
tein adsorption and activation at the surface in more detail
and seek to reduce it. To reduce it, surface coatings could
be employed that create a smoother and less adsorptive
surface. This top-coat must be thin, however, such that it
does not signiﬁcantly inhibit hydration, corrosion, and ioni-
zation of copper at the blood/polymer interface.
Circuits with NO ﬂux also maintained baseline white
blood cell counts, whereas control circuits caused a signiﬁ-
cant increase. Further studies are necessary to determine
the cause in these devices, but previous research suggests a
possible mechanism. Activated platelets are known to
release chemokines, including RANTES, platelet factor 4,
and epithelial neutrophil-activating protein 78.28,29 If this is
occurring in this study, it may draw monocytes to the sur-
face and further accelerate clot formation and systemic
inﬂammation. Platelet P-selectin binds monocytes ﬁrst via
their P-selectin glycoprotein (PSGL-1) and, afterwards, form
ﬁrmer bonds between monocyte CD11b/CD18 and platelet
GPIba directly and GpIIb/IIIa indirectly using ﬁbrinogen as
a bridging molecule.28,30 This, in turn, activates the mono-
cyte, causing it to release both pro-coagulant and pro-
inﬂammatory molecules. Major et al.24 demonstrated that
NO ﬂux from tubing in extracorporeal circuits decreased
monocyte activation, as demonstrated by CD11b expression.
It is also possible that NO has a more direct effect on white
cells but this has not yet been demonstrated.
The main disadvantage of NOgen is leaching of copper
into blood. Although copper is an essential trace element
present in normal diet, excess of it in serum can be toxic.
Potential adverse effects of copper toxicity include irritation
of the eyes, mouth, and nose, nausea, liver and kidney fail-
ure, and even loss of life after a high intake. According to
the food and drug administration (FDA), about 2 mg of cop-
per per day is required by the average adult with an accept-
able daily intake of 0.5 mg per kg body weight. Thus, the
acceptable daily total Cu intake could be 37 mg for a 75 kg
man with 5 L total blood volume. If absorbed all at once,
this would lead to a blood copper concentration of 750 lg/
dL. The amount of copper in the blood was 333 6 3.9 lg/
dL after 4 h but does not include any copper diffusing into
tissues. It is unclear if this level would lead to toxic effects.
Ultimately, further, long-term studies are required to
examine device biocompatibility. This includes coagulation,
inﬂammation, copper leaching, and their effect on organ
function over a period of weeks. If copper leaching leads to
toxicity, this will limit the clinical applicability of this
approach to short-term procedures such as cardiopulmo-
nary bypass, dialysis, and to small surface area devices such
as catheters, vascular grafts, patches, and stents. If this is
proven to be a problem, alternate or mixed catalysts such
as organoselenium could be explored.31
CONCLUSION
This study evaluated the ﬁrst Cu-mediated NO-generating
hollow silicone ﬁber lung in an ECC setup. The results indi-
cate that NO-generating hollow ﬁber lungs signiﬁcantly
reduce blood coagulation compared to their non-NO-gener-
ating controls. The resistance of the NO generating artiﬁcial
lungs did not change signiﬁcantly over the course of 4 h,
while the 60% of the control lungs occluded completely.
Accordingly, the control group had signiﬁcant lower blood
ﬂow and signiﬁcantly higher resistance due to occlusive clot
formation.
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